A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Steven A. Limentani, Mario Csampone, Thierry Dorval, Giuseppe Curigliano, Richard de Boer, Charles Vogel, Shane White, Thomas Bachelot, Jean Luc Canon, Mary Disis, Ahmad Awada, Martine Berlière, Frédéric Amant, Ellis Levine, Wivine Burny, Andrea Callegaro, Pedro Miguel De Sousa Alves, Jamila Louahed, Vincent Brichard, Frédéric F. Lehmann

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This Phase I dose-escalation study (NCT000 58526) assessed the safety and immunogenicity of an anticancer immunotherapeutic (recombinant HER2 protein (dHER2) combined with the immunostimulant AS15) in patients with early-stage HER2-overexpressing breast cancer (BC). Sixty-one trastuzumab-naive patients with stage II–III HER2-positive BC received the dHER2 immunotherapeutic after surgical resection and adjuvant therapy. They were allocated into four cohorts receiving different doses of dHER2 (20, 100, 500 μg) combined with a fixed AS15 dose. Safety and immunogenicity (dHER2-specific antibody responses) were assessed. After completing the immunization schedule (three or six doses over 14 weeks) and a six-month follow-up, the patients were followed for 5 years for late toxicity, long-term immunogenicity, and clinical status. The immunizations were well tolerated, and increasing doses of dHER2 had no impact on the frequency or severity of adverse events. Few late toxicities were reported, and after 5 years 45/54 patients(83.3 %) were still alive, while 28/45 (62 %) with known disease status were disease free. Regarding the immunogenicity of the compound, a positive association was found between the dHER2 dose, the immunization schedule, and the prevalence of dHER2-specific humoral responses. Among the patients receiving the most intense immunization schedule with the highest dHER2 dose, 6/8 maintained their dHER2-specific antibody response 5 years after immunization. The dHER2 immunotherapeutic had an acceptable safety profile in early HER2-positive BC patients. dHER2-specific antibody responses were induced, with the rate of responders increasing with the dHER2 dose and the number and frequency of immunizations.

Original languageEnglish (US)
Pages (from-to)319-330
Number of pages12
JournalBreast Cancer Research and Treatment
Volume156
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Breast Neoplasms
Immunization Schedule
Antibody Formation
Immunization
Neoplasms
Proteins
Safety
Therapeutics
Immunologic Adjuvants
Recombinant Proteins

Keywords

  • Cancer immunotherapeutic
  • DHER2 protein
  • HER2-overexpressing breast cancer
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. / Limentani, Steven A.; Csampone, Mario; Dorval, Thierry; Curigliano, Giuseppe; de Boer, Richard; Vogel, Charles; White, Shane; Bachelot, Thomas; Canon, Jean Luc; Disis, Mary; Awada, Ahmad; Berlière, Martine; Amant, Frédéric; Levine, Ellis; Burny, Wivine; Callegaro, Andrea; De Sousa Alves, Pedro Miguel; Louahed, Jamila; Brichard, Vincent; Lehmann, Frédéric F.

In: Breast Cancer Research and Treatment, Vol. 156, No. 2, 2016, p. 319-330.

Research output: Contribution to journalArticle

Limentani, SA, Csampone, M, Dorval, T, Curigliano, G, de Boer, R, Vogel, C, White, S, Bachelot, T, Canon, JL, Disis, M, Awada, A, Berlière, M, Amant, F, Levine, E, Burny, W, Callegaro, A, De Sousa Alves, PM, Louahed, J, Brichard, V & Lehmann, FF 2016, 'A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors', Breast Cancer Research and Treatment, vol. 156, no. 2, pp. 319-330. https://doi.org/10.1007/s10549-016-3751-x
Limentani, Steven A. ; Csampone, Mario ; Dorval, Thierry ; Curigliano, Giuseppe ; de Boer, Richard ; Vogel, Charles ; White, Shane ; Bachelot, Thomas ; Canon, Jean Luc ; Disis, Mary ; Awada, Ahmad ; Berlière, Martine ; Amant, Frédéric ; Levine, Ellis ; Burny, Wivine ; Callegaro, Andrea ; De Sousa Alves, Pedro Miguel ; Louahed, Jamila ; Brichard, Vincent ; Lehmann, Frédéric F. / A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. In: Breast Cancer Research and Treatment. 2016 ; Vol. 156, No. 2. pp. 319-330.
@article{a509afdd920c448986eb40f7034710eb,
title = "A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors",
abstract = "This Phase I dose-escalation study (NCT000 58526) assessed the safety and immunogenicity of an anticancer immunotherapeutic (recombinant HER2 protein (dHER2) combined with the immunostimulant AS15) in patients with early-stage HER2-overexpressing breast cancer (BC). Sixty-one trastuzumab-naive patients with stage II–III HER2-positive BC received the dHER2 immunotherapeutic after surgical resection and adjuvant therapy. They were allocated into four cohorts receiving different doses of dHER2 (20, 100, 500 μg) combined with a fixed AS15 dose. Safety and immunogenicity (dHER2-specific antibody responses) were assessed. After completing the immunization schedule (three or six doses over 14 weeks) and a six-month follow-up, the patients were followed for 5 years for late toxicity, long-term immunogenicity, and clinical status. The immunizations were well tolerated, and increasing doses of dHER2 had no impact on the frequency or severity of adverse events. Few late toxicities were reported, and after 5 years 45/54 patients(83.3 {\%}) were still alive, while 28/45 (62 {\%}) with known disease status were disease free. Regarding the immunogenicity of the compound, a positive association was found between the dHER2 dose, the immunization schedule, and the prevalence of dHER2-specific humoral responses. Among the patients receiving the most intense immunization schedule with the highest dHER2 dose, 6/8 maintained their dHER2-specific antibody response 5 years after immunization. The dHER2 immunotherapeutic had an acceptable safety profile in early HER2-positive BC patients. dHER2-specific antibody responses were induced, with the rate of responders increasing with the dHER2 dose and the number and frequency of immunizations.",
keywords = "Cancer immunotherapeutic, DHER2 protein, HER2-overexpressing breast cancer, Vaccine",
author = "Limentani, {Steven A.} and Mario Csampone and Thierry Dorval and Giuseppe Curigliano and {de Boer}, Richard and Charles Vogel and Shane White and Thomas Bachelot and Canon, {Jean Luc} and Mary Disis and Ahmad Awada and Martine Berli{\`e}re and Fr{\'e}d{\'e}ric Amant and Ellis Levine and Wivine Burny and Andrea Callegaro and {De Sousa Alves}, {Pedro Miguel} and Jamila Louahed and Vincent Brichard and Lehmann, {Fr{\'e}d{\'e}ric F.}",
year = "2016",
doi = "10.1007/s10549-016-3751-x",
language = "English (US)",
volume = "156",
pages = "319--330",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

AU - Limentani, Steven A.

AU - Csampone, Mario

AU - Dorval, Thierry

AU - Curigliano, Giuseppe

AU - de Boer, Richard

AU - Vogel, Charles

AU - White, Shane

AU - Bachelot, Thomas

AU - Canon, Jean Luc

AU - Disis, Mary

AU - Awada, Ahmad

AU - Berlière, Martine

AU - Amant, Frédéric

AU - Levine, Ellis

AU - Burny, Wivine

AU - Callegaro, Andrea

AU - De Sousa Alves, Pedro Miguel

AU - Louahed, Jamila

AU - Brichard, Vincent

AU - Lehmann, Frédéric F.

PY - 2016

Y1 - 2016

N2 - This Phase I dose-escalation study (NCT000 58526) assessed the safety and immunogenicity of an anticancer immunotherapeutic (recombinant HER2 protein (dHER2) combined with the immunostimulant AS15) in patients with early-stage HER2-overexpressing breast cancer (BC). Sixty-one trastuzumab-naive patients with stage II–III HER2-positive BC received the dHER2 immunotherapeutic after surgical resection and adjuvant therapy. They were allocated into four cohorts receiving different doses of dHER2 (20, 100, 500 μg) combined with a fixed AS15 dose. Safety and immunogenicity (dHER2-specific antibody responses) were assessed. After completing the immunization schedule (three or six doses over 14 weeks) and a six-month follow-up, the patients were followed for 5 years for late toxicity, long-term immunogenicity, and clinical status. The immunizations were well tolerated, and increasing doses of dHER2 had no impact on the frequency or severity of adverse events. Few late toxicities were reported, and after 5 years 45/54 patients(83.3 %) were still alive, while 28/45 (62 %) with known disease status were disease free. Regarding the immunogenicity of the compound, a positive association was found between the dHER2 dose, the immunization schedule, and the prevalence of dHER2-specific humoral responses. Among the patients receiving the most intense immunization schedule with the highest dHER2 dose, 6/8 maintained their dHER2-specific antibody response 5 years after immunization. The dHER2 immunotherapeutic had an acceptable safety profile in early HER2-positive BC patients. dHER2-specific antibody responses were induced, with the rate of responders increasing with the dHER2 dose and the number and frequency of immunizations.

AB - This Phase I dose-escalation study (NCT000 58526) assessed the safety and immunogenicity of an anticancer immunotherapeutic (recombinant HER2 protein (dHER2) combined with the immunostimulant AS15) in patients with early-stage HER2-overexpressing breast cancer (BC). Sixty-one trastuzumab-naive patients with stage II–III HER2-positive BC received the dHER2 immunotherapeutic after surgical resection and adjuvant therapy. They were allocated into four cohorts receiving different doses of dHER2 (20, 100, 500 μg) combined with a fixed AS15 dose. Safety and immunogenicity (dHER2-specific antibody responses) were assessed. After completing the immunization schedule (three or six doses over 14 weeks) and a six-month follow-up, the patients were followed for 5 years for late toxicity, long-term immunogenicity, and clinical status. The immunizations were well tolerated, and increasing doses of dHER2 had no impact on the frequency or severity of adverse events. Few late toxicities were reported, and after 5 years 45/54 patients(83.3 %) were still alive, while 28/45 (62 %) with known disease status were disease free. Regarding the immunogenicity of the compound, a positive association was found between the dHER2 dose, the immunization schedule, and the prevalence of dHER2-specific humoral responses. Among the patients receiving the most intense immunization schedule with the highest dHER2 dose, 6/8 maintained their dHER2-specific antibody response 5 years after immunization. The dHER2 immunotherapeutic had an acceptable safety profile in early HER2-positive BC patients. dHER2-specific antibody responses were induced, with the rate of responders increasing with the dHER2 dose and the number and frequency of immunizations.

KW - Cancer immunotherapeutic

KW - DHER2 protein

KW - HER2-overexpressing breast cancer

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85007189742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007189742&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3751-x

DO - 10.1007/s10549-016-3751-x

M3 - Article

VL - 156

SP - 319

EP - 330

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -